Company Analysis
Sign in

CG Oncology, Inc. (CGON)

Nasdaq: CGON · Biological Products, (No Diagnostic Substances) · Irvine, CA · filing with the SEC since 2023
Full chart Alerts Compare
Grade5.6
◀ Past 5.4● Present 5.7▶ Future 5.6
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$4.0M+254.7%
Net income-$161M-82.9%
Earnings per share$-2.08-47.5%
Operating cash flow-$132M-68.1%
Cash$32.5M-87.4%
Debt$3.0M
Shareholders’ equity$753M+2.6%
Shares, diluted77.3M+23.7%
Return on equity-21.4%
The recordfrom its filings
Filings in 202684
Newest filingNov 6 · 10-Q
Annual reportFeb 27, 2026
Quarterly reportNov 6, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$4.8M
Insider buys, 12 months$24.8M
Patents granted5
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $6.2MNet income -$237MCash from operations -$187Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Nov 6, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 6, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 17, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CGON · research, not advice